Peripheral T-cell lymphoma unspecified refractory – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:17 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Peripheral T-cell lymphoma unspecified refractory – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Azacitidine, Roginolisib, and Golcadomide for Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas https://clinicaltrials.eu/trial/study-on-azacitidine-roginolisib-and-golcadomide-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas/ Wed, 29 Apr 2026 15:05:07 +0000 https://clinicaltrials.eu/trial/study-on-azacitidine-roginolisib-and-golcadomide-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas/ This clinical trial is focused on studying new treatments for a type of cancer called Peripheral T-Cell Lymphoma that has either returned after treatment or has not responded to previous treatments. The study will explore the effects of several medications, including Azacitidine, IOA-244 (also known as Roginolisib), and Golcadomide (also referred to by its code name CC-99282). These medications are being tested to see if they can improve outcomes for patients with this challenging condition.

The purpose of the study is to determine the safety and tolerability of these medications, as well as to identify the most effective doses. The study will be conducted in two phases. In the first phase, researchers will focus on finding the safest dose of the medications by gradually increasing the dose and monitoring for any side effects. In the second phase, the study will aim to identify which of these medications, or combinations of them, can significantly improve the condition of patients with relapsed or refractory Peripheral T-Cell Lymphoma.

Participants in the study will receive one or more of the study medications in the form of tablets or capsules, taken orally. The study will monitor participants over time to assess how well the medications are working and to check for any side effects. The ultimate goal is to find new and effective treatment options for patients with this type of lymphoma, improving their quality of life and potentially extending their survival.

]]>